BioPharma Credit PLC Dividend Declaration (6412S)
08 November 2019 - 2:00AM
UK Regulatory
TIDMBPCR
RNS Number : 6412S
BioPharma Credit PLC
07 November 2019
BIOPHARMA CREDIT PLC
("BIOPHARMA CREDIT" OR THE "COMPANY")
DIVIDEND DECLARATION
BioPharma Credit PLC (LSE: BPCR), the specialist life sciences
debt investor, is pleased to declare an interim dividend in respect
of the financial period ending 30 September 2019 of $0.0175 per
ordinary share, payable on 17 December 2019 to ordinary
shareholders on the register as at 15 November 2019. The Company
has chosen to designate the entire amount of this interim dividend
as an interest distribution. Shareholders in receipt of such a
dividend will be treated for UK tax purposes as though they have
received a payment of interest. This will result in a reduction in
the corporation tax payable by the Company.
The Company is currently paying and continues to target a 7 cent
annual dividend per ordinary share.
The default payment for dividends is in US dollars. However,
shareholders can elect to have dividends paid in sterling (GBP) and
the option to elect a sterling dividend payment for this dividend
will be available to shareholders until 15 November 2019 (the
"Election Date").
Further details together with a copy of the Dividend Currency
Election Form, which should be sent to Link Asset Services, The
Registry, 34 Beckenham Road, Beckenham, Kent, BR3 4TU when
completed, will be available on the Group's website shortly at
www.bpcruk.com/investor-materials. CREST shareholders must elect
via CREST.
LEI: 213800AV55PYXAS7SY24
-Ends-
Link Company Matters Limited
Company Secretary
7 November 2019
Enquiries:
Buchanan
David Rydell / Mark Court / Jamie Hooper / Henry Wilson
+44 (0)20 7466 5000
Biopharmacredit@buchanan.uk.com
Notes to Editors:
BioPharma Credit PLC is London's only listed specialist investor
in debt from the life sciences industry and joined the LSE on 27
March 2017. The Company seeks to provide long-term shareholder
returns, principally in the form of sustainable income
distributions from exposure to the life sciences industry. The
Company seeks to achieve this objective primarily through
investments in debt assets secured by royalties or other cash flows
derived from the sales of approved life sciences products.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DIVBRBLTMBAMMIL
(END) Dow Jones Newswires
November 07, 2019 10:00 ET (15:00 GMT)
Biopharma Credit (LSE:BPCR)
Historical Stock Chart
From Apr 2024 to May 2024
Biopharma Credit (LSE:BPCR)
Historical Stock Chart
From May 2023 to May 2024